Biogen Idec (BIIB)
$226.40
1.15 (0.51%)
BIIB Stock Quote Delayed 30 Minutes
BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing
Biogen (BIIB) stock is a hot topic among traders Monday as the company's share resumed trading following a halt that was in effect on Friday.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
32.60B
PE Ratio
35.94
EPS
6.3
Volume (Avg. Vol.)
851,788
Day's Range
$222.38 - $227.63
52-Week Range
$189.44 - $280.41
Dividend & Yield
N/A (N/A)
BIIB Stock Predictions, Articles, and Biogen Idec News
Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock?
Biogen is in focus today with the company's lecanemab drug set for an FDA decision on approval, leading to bullish bets on BIIB stock.
BIIB Stock Alert: What the Latest Alzheimer’s Drug Data Means for Biogen
Biogen (BIIB) stock is on the move Wednesday after the company provided the latest update on its Alzheimer's drug candidate.
Why Is Biogen (BIIB) Stock Up Today?
Biogen (BIIB) stock is rising higher on Monday after Roche's (RHHBY) Alzheimer's drug didn't perform well in a clinical trial.
Hey Biogen Investors, Don’t Chase BIIB Stock!
If BIIB stock already reflects Biogen's early-stage Alzheimer's disease study results, then the next move could easily be to the downside.
Why Is Biogen (BIIB) Stock Up 40% Today?
Positive results from a clinical trial offer encouragement for the medical community, as well as for downtrodden BIIB stock investors.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning.
Biotech Stocks Stand to Benefit as Biden Announces Support for Industry
President Biden has announced a new initiative to help U.S. biotech producers grow. Here's what this news means for biotech stocks.
Biogen (BIIB) Stock Dips Following Q2 Earnings Report
Biogen delivered a Q2 beat on the top and bottom lines, but a lack of important disclosures is hurting sentiment for BIIB stock.
BIIB Stock Treks Higher Amid News That Biogen CEO Michel Vounatsos Is Stepping Down
Drug-making giant Biogen is in the green today after announcing CEO Michel Vounatsos is stepping down from the role.
Biogen’s Aduhelm Crashes the Biotech Sector
Aduhelm is an Alzheimer's treatment, not a cure. Its quick approval and high price have set off pushback on the whole FDA and Medicare drug process.
Why Is Biogen (BIIB) Stock in the Spotlight Today?
Medicare's decision not to cover the cost of the drug maker's expensive Alzheimer's drug is hitting the company's stock price today.
